ライフサイエンスコーパス: beta-hydroxybutyrate

1 on ( VCO2 ) and production of ketone bodies (beta-hydroxybutyrate).

2 y increased acylcarnitines (ACs) and reduced beta-hydroxybutyrate.

3 ol and urea at physiological pH, but not for beta-hydroxybutyrate.

4 s the inability of the hbd mutant to grow on beta-hydroxybutyrate.

5 ffer and glucose, or glucose plus insulin or beta-hydroxybutyrate.

6 els, with no increase in free fatty acids or beta-hydroxybutyrate.

7 orol), with different properties and without beta-hydroxybutyrate.

8 xide (epoxypropane) to form acetoacetate and beta-hydroxybutyrate.

9 toms of the endogenous storage compound poly-beta-hydroxybutyrate.

10 ic efficiency on 4-oxo-l-proline than on (R)-beta-hydroxybutyrate.

11 oacetyl-CoA), butyryl CoA, acetoacetate, and beta-hydroxybutyrate.

12 were observed on exogenous administration of beta-hydroxybutyrate.

13 rved after direct ventricular application of beta-hydroxybutyrate.

14 ion with increased myocardial utilization of beta-hydroxybutyrate.

15 y content) of glucose, free fatty acids, and beta-hydroxybutyrate.

16 codes a transporter of the major ketone body beta-hydroxybutyrate.

17 he endogenous ligand for the receptor may be beta-hydroxybutyrate.

18 e (4.83 x 10(-2) +/- 1.25 x 10(-2) s(-1)) or beta-hydroxybutyrate (4.11 x 10(-2) +/- 0.62 x 10(-2) s(

19 iously, isotonic solution (IS) enriched with beta-hydroxybutyrate, a nonlactate-generating substrate,

20 beta-hydroxybutyrate, a primary circulating ketone body

21 ions between C(4) ketogenesis (production of beta-hydroxybutyrate + acetoacetate), C(5) ketogenesis (

22 Ketone bodies (d-beta-hydroxybutyrate, acetoacetate) are increasingly rec

23 one bodies are comprised of three compounds (beta-hydroxybutyrate, acetoacetate, and acetone) that ci

24 ficantly increased the output of 13C-labeled beta-hydroxybutyrate, acetoacetate, and CO2, indicating

25 agmatine increased synthesis of 13C-labeled beta-hydroxybutyrate, acetoacetate, and N-acetylglutamat

26 on of acetoacetate yields a markedly reduced beta-hydroxybutyrate:acetoacetate ratio of 1:3, compared

27 otentially beneficial decreases in ferritin, beta-hydroxybutyrate, acetone, and ketone bodies, with a

28 cerol content and 2-fold increases in plasma beta-hydroxybutyrate, acylcarnitines, and hepatic mRNA e

29 similar rescue through increased amounts of beta-hydroxybutyrate, an endogenous HDACi.

30 otope infusions of: [D(7)]glucose, [(13)C(4)]beta-hydroxybutyrate and [3-(13)C]lactate before and aft

31 dditional pleotropic signaling properties of beta-hydroxybutyrate and AcAc are discussed including ep

32 The ketone bodies beta-hydroxybutyrate and acetoacetate are hepatically pr

33 Both 3-beta-hydroxybutyrate and acetoacetate+acetone individual

34 -limiting enzyme for myocardial oxidation of beta-hydroxybutyrate and acetoacetate.

35 These metabolites were identified as beta-hydroxybutyrate and acetoacetate.

36 derlying mechanisms by testing the effect of beta-hydroxybutyrate and octanoate on rat hippocampal sy

37 parations were used to assess the ability of beta-hydroxybutyrate and octanoate to support neuronal a

38 respiratory quotient, together with elevated beta-hydroxybutyrate and reduced plasma fatty acid level

39 se-dependently reduced the levels of hepatic beta-hydroxybutyrate and repressed ketone body biosynthe

40 Serum beta-hydroxybutyrate and total ketone levels significant

41 This enzyme can sense cellular beta-hydroxybutyrate and translocate into the nucleus, w

42 d with both hyperketonemia (acetoacetate and beta-hydroxybutyrate) and hyperglycemia.

43 eased plasma and liver triglycerides, plasma beta-hydroxybutyrate, and insulin.

44 with McCarey-Kaufman medium, with or without beta-hydroxybutyrate, and other known media (Optisol and

45 ts had reduced body weight, increased plasma beta-hydroxybutyrate, and reduced plasma insulin compare

46 A derivatives, hydroxysteroids, alcohols and beta-hydroxybutyrate, and the capacity to bind amyloid-b

47 Amino acids, beta-hydroxybutyrate, and tricarboxylic acid cycle inter

48 hain amino acids, nonesterified fatty acids, beta-hydroxybutyrate, and urinary nitrogen but no change

49 Further, the ketone body beta-hydroxybutyrate, another metabolite that impacts re

50 When placed in medium with d-beta-hydroxybutyrate as the principal energy substrate,

51 beta-Hydroxybutyrate augmented insulin secretion in huma

52 Body composition, plasma concentration of beta-hydroxybutyrate (beta-HB) and appetite-related horm

53 on of the ketone body acetoacetate (AcAc) to beta-hydroxybutyrate (beta-HB) by the mitochondrial enzy

54 hat RPE cells, like hepatocytes, can produce beta-hydroxybutyrate (beta-HB) from fatty acids.

55 We found increased levels of beta-hydroxybutyrate (beta-HB) in the apical medium foll

56 r for the vitamin niacin and the ketone body beta-hydroxybutyrate (beta-HB).

57 (EF) <=50% received incremental infusions of beta-hydroxybutyrate (beta-OH-B) for 3-6 h to increase t

58 er (KME) supplements rapidly increase plasma beta-hydroxybutyrate (beta-OHB) and may impact cerebral

59 However, VMH beta-hydroxybutyrate (beta-OHB) and VMH-to-serum beta-OH

60 f ketone monoester intake and elevated blood beta-hydroxybutyrate (beta-OHB) concentration, with and

61 Beta-hydroxybutyrate (beta-OHB) is a signalling molecule

62 c patients had similar ISR but higher plasma beta-hydroxybutyrate (beta-OHB) levels during L/H infusi

63 nergy substrates, we examined the effects of beta-hydroxybutyrate (betaHB) on synaptic transmission a

64 anaplerosis and potentially therefore for d-beta-hydroxybutyrate (betaHB) oxidation.

65 Beta-hydroxybutyrate (betaHB), a ketone body produced du

66 An increased concentration of beta-hydroxybutyrate (betaHBA) is a key biomarker for di

67 we identified ketone bodies (KBs)-including beta-hydroxybutyrate (betaOHB) and acetoacetate (AcAc)-a

68 can activate ketone body metabolism and that beta-hydroxybutyrate (betaOHB) is an alternative cell-in

69 We report that the ketone body d-beta-hydroxybutyrate (betaOHB) is an endogenous and spec

70 n the production of ketone bodies, including beta-hydroxybutyrate (betaOHB), distinguishes self-renew

71 We have investigated whether beta-hydroxybutyrate (betaOHB), the main ketone body (KB

72 litude daily rhythms in blood ketone bodies (beta-hydroxybutyrate [betaOHB]) that correlated with liv

73 The ketone bodies beta-hydroxybutyrate (BHB) and acetoacetate (AcAc) suppo

74 stand the relationship between point-of-care beta-hydroxybutyrate (BHB) and different patterns of MGU

75 aracterized by an increase in serum level of beta-hydroxybutyrate (BHB) and the activation of AMPK, a

76 In this study, we use beta-hydroxybutyrate (BHB) dehydrogenase (BHBDh) from Al

77 hyl fumarate and the HCAR2 endogenous ligand beta-hydroxybutyrate (BHB) in wild-type (WT) and HCAR2-n

78 Beta-hydroxybutyrate (BHB) is a ketone body and has rece

79 beta-Hydroxybutyrate (BHB) is an abundant ketone body.

80 The ketone body beta-hydroxybutyrate (BHB) is synthesized in the liver f

81 r to the KD to achieve MGS and whether serum beta-hydroxybutyrate (BHB) levels can predict MGS.

82 Furthermore, THC increased beta-hydroxybutyrate (BHB) levels via a CBR1-mediated me

83 s of glucose deprivation and the ketone body beta-hydroxybutyrate (BHB) on inflammatory gene expressi

84 vein concentrations of lactate, pyruvate, or beta-hydroxybutyrate (BHB) on the sympathoadrenal respon

85 er fasting conditions, this mutation reduced beta-hydroxybutyrate (BHB) plasma levels as well as BHB

86 g et al.(1) demonstrate that the ketone body beta-hydroxybutyrate (BHB) promotes the biogenesis of mi

87 The concentration of beta-hydroxybutyrate (BHB) was determined in serum and u

88 ne bodies (acetone, acetoacetate (AcAc), and beta-hydroxybutyrate (BHB)) serve as an alternative ener

89 ondrial ketogenic pathway" (MKP) to generate beta-hydroxybutyrate (BHB), a ketone body.

90 tion to acetate and propionate, we show that beta-hydroxybutyrate (BHB), a metabolite produced during

91 vels of the ketone bodies acetoacetate (AA), beta-hydroxybutyrate (BHB), and acetone (ACE).

92 red that the major component of ketone body, beta-hydroxybutyrate (BHB), improved mitochondrial funct

93 It has been reported that beta-hydroxybutyrate (BHB), one of the main ketone bodie

94 r dietary supplementation of the ketone body beta-hydroxybutyrate (BHB), which is an endogenous HDACi

95 c diets are recapitulated by the ketone body beta-hydroxybutyrate (BHB), which reduces the proliferat

96 rbohydrate diets lead to the accumulation of beta-hydroxybutyrate (BHB), whose blood concentrations c

97 d analytical device (pop-up-EPAD) to measure beta-hydroxybutyrate (BHB)-a biomarker for diabetic keto

98 plasma non-esterified fatty acids (NEFA) and beta-hydroxybutyrate (BHB).

99 h elevated levels of acetoacetate (AcAc) and beta-hydroxybutyrate (BHB).

100 ed with ketone bodies (acetoacetate [AA] and beta-hydroxybutyrate [BHB]) in the presence or absence o

101 , phenylalanine, tyrosine, valine, glycerol, beta -hydroxybutyrate (BHBA), and acetate were predicted

102 levels of hepatic PEPCK mRNA, blood glucose, beta-hydroxybutyrate, blood urea nitrogen, and gluconeog

103 e found that physiological concentrations of beta-hydroxybutyrate (BOH) induced proteolysis in cells

104 olism, as validated by parallel venous blood beta-hydroxybutyrate (BOHB) measurements.

105 atched glucose and exogenous ketone ester (d-beta-hydroxybutyrate) bolus.

106 ctrophysiological measurements indicate that beta-hydroxybutyrate causes an increase in neurotransmit

107 he appropriate substrate, the copolymer poly(beta-hydroxybutyrate-co-beta-hydroxyvalerate) (PHBV).

108 fasting whole-body fat oxidation and plasma beta-hydroxybutyrate concentration increased, whereas ma

109 a, microdomains convert the high glucose and beta-hydroxybutyrate concentration signals to the negati

110 -oxidation enzyme activity and portal plasma beta-hydroxybutyrate concentration without significantly

111 sion to beta-hydroxybutyrate; higher fasting beta-hydroxybutyrate concentration; slower beta-hydroxyb

112 orimetry), and ketogenesis (from circulating beta-hydroxybutyrate concentrations).

113 tivation, phosphorylation of ACC, and plasma beta-hydroxybutyrate concentrations.

114 Measures of beta-hydroxybutyrate confirmed that all participants wer

115 higher in the presence of the ketone body R-beta-hydroxybutyrate, consistent with earlier findings t

116 ct of the acute administration of a ketone d-beta-hydroxybutyrate (D-betaHB) monoester in fasting hea

117 that the fatty acid-derived ketone body (D)-beta-hydroxybutyrate ((D)-beta-OHB) specifically activat

118 show that the infusion of the ketone body d-beta-hydroxybutyrate (DbetaHB) in mice confers partial p

119 ion of cellular energy with a ketone body, D-beta-hydroxybutyrate, decreased rotenone toxicity in MN9

120 tyrate (beta-HB) by the mitochondrial enzyme beta-hydroxybutyrate dehydrogenase (BDH) depends upon NA

121 sly annotated mammalian cytosolic type 2 (R)-beta-hydroxybutyrate dehydrogenase (BDH2) emerged as the

122 containing toluidine blue O (TBO mediator), beta-hydroxybutyrate dehydrogenase (HBD enzyme), and the

123 ime HB detection has been realized using the beta-hydroxybutyrate dehydrogenase (HBD) enzymatic react

124 In addition, a gene encoding beta-hydroxybutyrate dehydrogenase (hbd) was identified.

125 Conversely, expression of beta-hydroxybutyrate dehydrogenase 1, a key enzyme in th

126 enzyme differs from all the presently known beta-hydroxybutyrate dehydrogenases which are well estab

127 ort the identification and verification of a beta-hydroxybutyrate-derived protein modification, lysin

128 Moreover, beta-hydroxybutyrate did not affect seizures in HCAR2(-)

129 roducts, while the degradation of glucose or beta-hydroxybutyrate did not.

130 We demonstrate that the beta-hydroxybutyrate drives the ACSS2-KAT7-H3K9bhb axis

131 Glucose- and beta-hydroxybutyrate-dually sensitive microdomains are i

132 nd that a diet enriched with the ketone body beta-hydroxybutyrate during early development induces DA

133 ntravenous infusion of the ketone body BOHB (beta-hydroxybutyrate) during the MI induction.

134 bitor of class I HDACs via the major product beta-hydroxybutyrate, elevates the level of histone acet

135 The time courses of acetoacetate and beta-hydroxybutyrate formaton indicate that acetoacetate

136 tes, including arabinose, malate, succinate, beta-hydroxybutyrate, glycerol, formate, and galactose.

137 In individuals with beta-hydroxybutyrate >154 umol/L (highest fourth) vs. in

138 s based on the electrochemical monitoring of beta-hydroxybutyrate (HB) as the dominant biomarker of k

139 g strip for rapid decentralized detection of beta-hydroxybutyrate (HB), one of the dominant physiolog

140 but KPD had slower acetyl CoA conversion to beta-hydroxybutyrate; higher fasting beta-hydroxybutyrat

141 In vivo oxidation of (13)C-labeled beta-hydroxybutyrate in neonatal Oxct1(-/-) mice, measur

142 hromatin regulation and diverse functions of beta-hydroxybutyrate in the context of important human p

143 Blood beta-hydroxybutyrate in the KLC dieters was 3.6 times th

144 x by application of pyruvate, iodoacetate or beta-hydroxybutyrate induced electromechanical and [Ca2+

145 Moreover, the most abundant ketone body, beta-hydroxybutyrate, inhibits the NLRP3 inflammasome in

146 ct of propylene oxide carboxylation and that beta-hydroxybutyrate is a secondary product formed by th

147 Since beta-hydroxybutyrate is both a major fuel and a signalin

148 However, the molecular mechanism by which beta-hydroxybutyrate is converted to beta-hydroxybutyryl

149 We have discovered that the action of beta-hydroxybutyrate is specifically upon HDAC2 and HDAC

150 lism, measured as higher plasma glycerol and beta-hydroxybutyrate, is associated with increased all-c

151 As in R. etli, a 4-carbon fatty acid, beta-hydroxybutyrate, is esterified to (omega - 1) of th

152 Changes in beta-hydroxybutyrate, isoleucine, lactate, and pyridoxat

153 okinin, elevated fatty acid oxidation, and 3-beta-hydroxybutyrate ketone levels, and reduced appetite

154 ents production of the fat breakdown product beta-hydroxybutyrate, leading to increased production of

155 s potential anticancer effects by increasing beta hydroxybutyrate levels.

156 However, ketosis (beta-hydroxybutyrate levels >500 mumol/L) was achieved i

157 rotein kinase B) and the ability to suppress beta-hydroxybutyrate levels are not impaired in TGN.

158 n hepatic acetyl-coenzyme A (acetyl-CoA) and beta-hydroxybutyrate levels as well as protein acetylati

159 es also produced higher free fatty acids and beta-hydroxybutyrate levels compared with placebo.

160 The KE-1 diet in mice elevated beta-hydroxybutyrate levels during nocturnal feeding, wh

161 ctively, TCDD reduced hepatic acetyl-CoA and beta-hydroxybutyrate levels eliciting starvation-like co

162 dramatically induced in response to elevated beta-hydroxybutyrate levels in cultured cells and in liv

163 Blood d-beta-hydroxybutyrate levels in the KE group were 3-5 tim

164 were enhanced; in patients with T2D, fasting beta-hydroxybutyrate levels rose from 246 +/- 288 to 561

165 Plasma 3-beta-hydroxybutyrate levels were increased 3-5 days afte

166 Fatty acid oxidation, as inferred from serum beta-hydroxybutyrate levels, was increased in response t

167 ted by changes in plasma free fatty acid and beta-hydroxybutyrate levels.

168 clonal antibody normalized blood glucose and beta-hydroxybutyrate levels.

169 umol/L (highest fourth) vs. individuals with beta-hydroxybutyrate <91 umol/L (lowest fourth), the mul

170 oA, the acetyl moiety of citrate, C-1 + 2 of beta-hydroxybutyrate, malonyl-CoA, and acetylcarnitine.

171 pigenetic modifications through elevation of beta-hydroxybutyrate may provide a feasible strategy to

172 following an epigenetic switch triggered by beta-hydroxybutyrate-mediated inhibition of HDAC3.

173 ysiological concentrations of ketone bodies (beta-hydroxybutyrate or acetoacetate) reduced the sponta

174 was decreased in the presence of insulin or beta-hydroxybutyrate or both (from 1.14 +/- 0.3 to 0.58

175 o structurally related molecules acetate and beta-hydroxybutyrate or cofactors NAD(+) and NADH.

176 apidly inhibited in hepatocytes incubated in beta-hydroxybutyrate or fatty acids, and the observed in

177 g glucose, free fatty acids (FFAs), lactate, beta-hydroxybutyrate, or insulin levels relative to cont

178 l, the mitochondrial complex II activator, D-beta-hydroxybutyrate, or the anti-apoptotic bile acid ta

179 o 0.58 +/- 0.16 [insulin], to 0.75 +/- 0.17 [beta-hydroxybutyrate] or to 0.53 +/- 0.17 [both], P < 0.

180 /- 0.2 micromol.kg(-1).min(-1)), net hepatic beta-hydroxybutyrate output (0.1 +/- 0.0 and 0.4 +/- 0.1

181 provide anaplerotic substrate to facilitate beta-hydroxybutyrate oxidation in isolated perfused rat

182 g beta-hydroxybutyrate concentration; slower beta-hydroxybutyrate oxidation; faster leucine oxidative

183 = 0.00004), peptide YY (PYY) (P = 0.01), and beta-hydroxybutyrate (P = 0.0001) were higher in MCT and

184 beta-Hydroxybutyrate permeability was not increased abov

185 eutropha produces both the homopolymer poly-beta-hydroxybutyrate (PHB) and, when provided with the a

186 e facultative methylotroph, accumulates poly-beta-hydroxybutyrate (PHB) as a carbon and energy reserv

187 NA regions containing genes involved in poly-beta-hydroxybutyrate (PHB) biosynthesis and degradation

188 The use of poly-beta-hydroxybutyrate (PHB) is an alternative polymer tha

189 To evaluate if the compound poly-beta-hydroxybutyrate (PHB) might be a suitable immunopro

190 Disruption of beta-hydroxybutyrate production increases hepatic NAD(+)

191 ctivated protein kinase, phenylpyruvate, and beta-hydroxybutyrate production previously associated wi

192 s were associated with increased circulating beta-hydroxybutyrate, PYY, and GIP, and suppression of a

193 olesterol was directly correlated with blood beta-hydroxybutyrate (r = 0.297, P = 0.025).

194 We measured the effects of a diet in which D-beta-hydroxybutyrate-(R)-1,3 butanediol monoester [keton

195 tment regimen using a commercially available beta-hydroxybutyrate-(R)-1,3-butanediol monoester (Delta

196 In mice with HCAR2, beta-hydroxybutyrate reduced neuronal excitability by hy

197 ld lower than wild-type hepatocytes, whereas beta-hydroxybutyrate release was increased 2-fold, suppo

198 ese findings demonstrate that HCAR2 mediates beta-hydroxybutyrate's antiseizure effects by regulating

199 ciated with activation of the renoprotective beta-hydroxybutyrate signaling pathway.

200 Inhibition of beta-hydroxybutyrate signalling or prostaglandin product

201 In hippocampal slices beta-hydroxybutyrate supported synaptic transmission und

202 ese bacteria and found that they can produce beta-hydroxybutyrate, supporting cardiac function post-M

203 beta-hydroxybutyrate suppressed excitatory synaptic tran

204 ers of SCOT-KO mice diminish de novo hepatic beta-hydroxybutyrate synthesis by 90%.

205 ower serum concentrations of fatty acids and beta-hydroxybutyrate than control mice, regardless of wh

206 entrations of non-esterified fatty acids and beta-hydroxybutyrate than mid-postpartum animals and con

207 ros, as well as suppressed the production of beta-hydroxybutyrate, the central metabolite of therapeu

208 patients in persistent AF revealed a rise in beta-hydroxybutyrate, the major substrate in ketone body

209 y to intracellular acetyl-CoA pools than did beta-hydroxybutyrate, the predominant circulating ketone

210 The KE increased d-beta-hydroxybutyrate to a maximum of ~3.4 mM (P < 0.001)

211 c activity, and reduced H2S levels; however, beta-hydroxybutyrate treatment had no effect.

212 s, respectively, with validated glucose- and beta-hydroxybutyrate-triggered insulin release.

213 NMR included BCAAs, trimethylamine N-oxide, beta-hydroxybutyrate, trimethyl uric acid, and alanine.

214 in/glucose (R = 0.89, P = .03) and increased beta-hydroxybutyrate uptake (R = 0.81, P = .05) during i

215 nase activity in villus tip cells and plasma beta-hydroxybutyrate values in portal vein and carotid a

216 ivity, as well as portal and arterial plasma beta-hydroxybutyrate values, were determined.

217 beta-hydroxybutyrate was 2- to 7-fold higher in INSR ver

218 CH) plus glutamine, or methyl succinate plus beta-hydroxybutyrate was also decreased in the PC knockd

219 The metabolic substrate beta-hydroxybutyrate was associated with reduced cytokin

220 beta-hydroxybutyrate was used as a second FFAR3 ligand,

221 onding values for higher plasma glycerol and beta-hydroxybutyrate were 1.37 (1.18-1.59) and 1.18 (1.0

222 isoleucine, valine, alanine, and alpha- and beta-hydroxybutyrate were found to have decreased concen

223 Serum concentrations of beta-hydroxybutyrate were greater with MCTs plus LCTs th

224 ylic acid cycle intermediates and the ketone beta-hydroxybutyrate were increased by 30%-80% in PBH ve

225 .05), whereas free fatty acid, glycerol, and beta-hydroxybutyrate were lower a.m. versus p.m. However

226 ions of insulin, glucose, FFAs, lactate, and beta-hydroxybutyrate were normal.

227 Plasma and urinary beta-hydroxybutyrate were similar on both diets.

228 troscopy), and hepatic fat oxidation (plasma beta-hydroxybutyrate) were measured.RESULTSLipolysis was

229 state (plasma triglycerides, uric acid, and beta-hydroxybutyrate), which suggests appetite suppressi

230 The metabolite beta-hydroxybutyrate, which increases after prolonged ex

231 rom glucose to alternative fuels, lactate or beta-hydroxybutyrate, while monitoring the spontaneous f

232 ion in all lines was achieved by combining d-beta-hydroxybutyrate with tauroursodeoxycholic acid but